Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK9 | P50750 | 6/20 | 0.42 |
| ▸ | CCNT1 | O60563 | 5/20 | 0.42 |
| ▸ | BTK | Q06187 | 4/20 | 0.40 |
| ▸ | WNT3A | P56704 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.37 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3436026 | 0.86 | CCNT1 (0.41) | CDK9CCNT1BTKKDM4ESIGMAR1 | |
| SCHEMBL3436613 | 0.84 | SIGMAR1 (0.42) | CDK9CCNT1BTKWNT3AKDM4E | |
| SCHEMBL3436711 | 0.81 | CCNT1 (0.43) | CDK9CCNT1BTKWNT3AKDM4E | |
| SCHEMBL3435647 | 0.81 | CDK9 (0.38) | CDK9CCNT1BTKKDM4EMAPT | |
| SCHEMBL3436504 | 0.81 | CDK9 (0.53) | CDK9CCNT1WNT3ASIGMAR1ATM | |
| SCHEMBL3436698 | 0.78 | CDK9 (0.55) | CDK9CCNT1SIGMAR1 | |
| SCHEMBL3435686 | 0.74 | SIGMAR1 (0.42) | CDK9CCNT1BTKKDM4EMAPT | |
| SCHEMBL3434496 | 0.74 | SIGMAR1 (0.40) | CDK9CCNT1KDM4EMAPTSIGMAR1 | |
| SCHEMBL3436614 | 0.72 | CCNT1 (0.48) | CDK9CCNT1WNT3AKDM4EMAPT | |
| SCHEMBL3436391 | 0.72 | KDM4E (0.45) | CDK9CCNT1WNT3AKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
| EP-2009005-A1 | AZOLECARBOXAMIDE DERIVATIVE | Astellas Pharma Inc. (JP) | 2008-12-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | GPR17, NTRK1, TRPV1 | CDK9 648/4885CCNT1 3047/4885BTK 1128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.